Nothing Special   »   [go: up one dir, main page]

ES2168322T3 - Sustancias acondicionadas solubles en agua. - Google Patents

Sustancias acondicionadas solubles en agua.

Info

Publication number
ES2168322T3
ES2168322T3 ES95111178T ES95111178T ES2168322T3 ES 2168322 T3 ES2168322 T3 ES 2168322T3 ES 95111178 T ES95111178 T ES 95111178T ES 95111178 T ES95111178 T ES 95111178T ES 2168322 T3 ES2168322 T3 ES 2168322T3
Authority
ES
Spain
Prior art keywords
water
soluble conditioning
conditioning substances
substances
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95111178T
Other languages
English (en)
Inventor
Katarina Ulla Bystrom
Edib Jakupovic
Jan William Trofast
Eva Ann-Christin Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20382434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2168322(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2168322T3 publication Critical patent/ES2168322T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paper (AREA)
  • Hydrogenated Pyridines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Treating Waste Gases (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

SE DESCRIBEN SUSTANCIAS MICRONIZADAS SOLUBLES EN AGUA, ES DECIR DROGAS Y EXCIPIENTES PARA ADMINISTRACION POR INHALACION, QUE TIENEN UN TAMAÑO DE PARTICULA MENOR DE 10{MI} Y TIENEN FORMA CRISTALINA ESTABLE EN LA QUE LA CAPA EXTERIOR DE LOS CRISTALINOS NO ES SUSTANCIALMENTE AMORFA O METASTABLE.
ES95111178T 1991-04-11 1992-03-24 Sustancias acondicionadas solubles en agua. Expired - Lifetime ES2168322T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101090A SE9101090D0 (sv) 1991-04-11 1991-04-11 Process for conditioning of water-soluble substances

Publications (1)

Publication Number Publication Date
ES2168322T3 true ES2168322T3 (es) 2002-06-16

Family

ID=20382434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92907877T Expired - Lifetime ES2086733T3 (es) 1991-04-11 1992-03-24 Procedimiento para acondicionar sustancias solubles en agua.
ES95111178T Expired - Lifetime ES2168322T3 (es) 1991-04-11 1992-03-24 Sustancias acondicionadas solubles en agua.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES92907877T Expired - Lifetime ES2086733T3 (es) 1991-04-11 1992-03-24 Procedimiento para acondicionar sustancias solubles en agua.

Country Status (28)

Country Link
US (1) US5562923A (es)
EP (3) EP0680752B1 (es)
JP (2) JP3400999B2 (es)
KR (1) KR100216384B1 (es)
AT (2) ATE137671T1 (es)
AU (1) AU662519B2 (es)
BG (1) BG61474B1 (es)
CA (1) CA2106975C (es)
CZ (1) CZ286936B6 (es)
DE (2) DE69210601T2 (es)
DK (2) DK0680752T3 (es)
EE (1) EE02970B1 (es)
ES (2) ES2086733T3 (es)
FI (1) FI105388B (es)
GR (1) GR3020602T3 (es)
HK (1) HK52497A (es)
HU (1) HU211116B (es)
IE (1) IE921144A1 (es)
IS (1) IS3834A (es)
NO (1) NO311867B1 (es)
PL (1) PL168232B1 (es)
PT (1) PT680752E (es)
RO (1) RO115779B1 (es)
RU (1) RU2112507C1 (es)
SE (1) SE9101090D0 (es)
SG (1) SG43180A1 (es)
SK (1) SK280310B6 (es)
WO (1) WO1992018110A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
CN1090935C (zh) * 1995-02-28 2002-09-18 阿温蒂斯药物公司 哌啶子基烷醇化合物的药物组合物
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP2036544B1 (en) * 1997-03-20 2016-12-28 Merck Sharp & Dohme Corp. Dosage form of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
CN1159012C (zh) * 1997-08-26 2004-07-28 阿旺蒂斯制药公司 用于组合哌啶子基烷醇-减充血剂的药物组合物
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
RS50182B (sr) * 1997-09-29 2009-05-06 Nektar Therapeutics, Perforisane mikročestice i postupci za njihovu primenu
FI105074B (fi) * 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6623760B1 (en) 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
EA018356B1 (ru) * 2003-06-13 2013-07-30 Джон Клод Савуар Микросферы эстрадиола и холестерина
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CN1894095A (zh) * 2003-10-17 2007-01-10 纳幕尔杜邦公司 箔对热塑性聚合物的粘合
US7544805B2 (en) 2004-02-03 2009-06-09 Chemagis Ltd. Stable amorphous forms of montelukast sodium
DE102004048390A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2009074662A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
AU2012277514A1 (en) 2011-06-29 2014-01-09 Astrazeneca Ab Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders
CA2905542C (en) * 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978192A (en) * 1971-09-23 1976-08-31 Sussman Martin V Method of drawing fibers using a microterraced drawing surface
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
EP0258258B1 (de) * 1985-06-21 1989-03-29 Gergely, Gerhard, Dr. Verfahren und vorrichtung zur behandlung von prozessgut, sowie mit hilfe des verfahrens und/oder der vorrichtung hergestelltes reaktivprodukt
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
KR100229754B1 (ko) * 1989-11-24 1999-11-15 샬러 한스, 하우스 한스 루돌프 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Also Published As

Publication number Publication date
DE69210601D1 (de) 1996-06-13
AU662519B2 (en) 1995-09-07
EP0508969A1 (en) 1992-10-14
NO933575L (no) 1993-10-06
EP0680752A3 (es) 1995-11-22
PT680752E (pt) 2002-05-31
DE69232207D1 (de) 2001-12-20
CA2106975A1 (en) 1992-10-12
DE69210601T2 (de) 1996-10-02
EP0580648A1 (en) 1994-02-02
SK108893A3 (en) 1994-03-09
CZ286936B6 (cs) 2000-08-16
FI934429A (fi) 1993-10-08
RU2112507C1 (ru) 1998-06-10
PL168232B1 (pl) 1996-01-31
DE69232207T2 (de) 2002-08-01
IE921144A1 (en) 1992-10-21
NO933575D0 (no) 1993-10-06
EE02970B1 (et) 1997-04-15
HUT65095A (en) 1994-04-28
SG43180A1 (en) 1997-10-17
ATE208613T1 (de) 2001-11-15
ES2086733T3 (es) 1996-07-01
JP2003155228A (ja) 2003-05-27
RO115779B1 (ro) 2000-06-30
ATE137671T1 (de) 1996-05-15
US5562923A (en) 1996-10-08
NO311867B1 (no) 2002-02-11
EP0680752B1 (en) 2001-11-14
HU9302870D0 (en) 1993-12-28
BG98147A (bg) 1994-12-02
DK0680752T3 (da) 2002-02-25
CZ211693A3 (en) 1994-04-13
SK280310B6 (sk) 1999-11-08
GR3020602T3 (en) 1996-10-31
AU1534792A (en) 1992-11-17
HU211116B (en) 1995-10-30
HK52497A (en) 1997-05-02
JP3400999B2 (ja) 2003-04-28
FI934429A0 (fi) 1993-10-08
FI105388B (fi) 2000-08-15
KR100216384B1 (ko) 1999-08-16
CA2106975C (en) 2002-03-19
BG61474B1 (en) 1997-09-30
SE9101090D0 (sv) 1991-04-11
EP0680752A2 (en) 1995-11-08
DK0580648T3 (da) 1996-09-16
EP0580648B1 (en) 1996-05-08
WO1992018110A1 (en) 1992-10-29
JPH06506454A (ja) 1994-07-21
IS3834A (is) 1992-10-12

Similar Documents

Publication Publication Date Title
ES2168322T3 (es) Sustancias acondicionadas solubles en agua.
DE3689252D1 (de) Arzneimittel gegen chronische Graft-versus-Host-Krankheiten sowie gegen Autoimmunerkrankungen, insbesondere systemischen Lupus erythematodes.
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
MX9101175A (es) Composicion farmaceutica para administracion nasal
ES513357A0 (es) "un sistema terapeutico bajo la forma de un vendaje para administrar el medicamento".
IT7928301A0 (it) Forme galeniche di somministrazione di medicamenti per via orale,a liberazione programmata,e loro procedimenti di preparazione
IT1148984B (it) Perfezionamento negli inalatori a dosaggio per la somministrazione di preparati farmacologici
IT8050314A0 (it) Dispositivo per la somministrazione di medicamenti in polvere
ATE203400T1 (de) Pharmazeutische formulierungen
DE3860550D1 (de) Pharmazeutische zubereitung fuer perkutane verabreichung, die eperison oder tolperison oder eines ihrer salze enthaelt.
LV10953A (lv) Aizvietotie benzimidazoli to iegusanas panemiens pielietojums farmaceitiska kompozicija
KR930007441A (ko) 의약품
ES2052911T3 (es) Tableta masticable.
FI923308A0 (fi) Foerbaettrade preparat innehaollande dideoxpurinnukleosider foer oral administration.
IT9019112A1 (it) Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
MX9203615A (es) Composicion farmaceutica en forma de polvo para administracion nasal.
FI941878A0 (fi) Uusia ioninvaihtajiin kytkettyjä lääkevalmisteita
ITRM920535A0 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
MX9205454A (es) Composicion farmaceutica para administracion oral al tracto gastrointestinal que comprende calcitonina
EP0345883A3 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
IT8322118A1 (it) Nuove composizioni farmaceutiche comprendenti epinina o un suo sale farmaceuticamente accettabile e loro uso terapeutico
BR9803319A (pt) Uso de inibidores do trocador sódio-hidrogênio paros indesejados de substâncias sobre o coração.
IT9021021A0 (it) Composizioni farmaceutiche per la somministrazione orale di irudina
SE8502876L (sv) Inhibering av tumorutveckling
O'Brien Ulcerogenic properties of anti-inflammatory drugs

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 680752

Country of ref document: ES